Our research investments deliver on the promise of making life with Type 1 Diabetes better. We’ve championed technology with that goal in mind, from the first engineered insulin 40 years ago to recent advancements like artificial pancreas systems and more.
Our powerhouse team in Washington, D.C., works with volunteers across the country to secure government support for innovative Type 1 Diabetes research. Meanwhile, our experts collaborate with regulators and health plans to help the entire community benefit from treatments and therapies.
The Outlook has Never Been Better
JDRF has changed the way we live with T1D. Everyday, we are learning more about the disease in an effort to end it once and for all.
Less than 50 years ago, insulins were derived from animals, and dosing was wildly inconsistent.
Synthetic insulins with a range of speeds and durations offer the precision and flexibility to better balance blood-sugar levels.
50 years ago, a prototype insulin pump was so large it had to be worn like a backpack.
Compact insulin pumps fit easily in a pocket—and they’ve gotten smarter too.
30 years ago, there was no way to predict if someone would develop T1D.
It is possible to detect T1D before symptoms arise, avoiding adverse side effects.
Beta Cell Biology
For decades, experts believed that beta cells stopped functioning altogether within a few years of T1D onset.
We know beta cells continue to function even after decades with T1D, and it might be possible to cure T1D by preserving or expanding these beta cells.
Diabetic Eye Disease
35 years ago, the risk of vision loss from diabetic eye disease was 50 percent.
State-of-the-art care has cut the risk to 5 percent, and therapies to eliminate the remaining risk are in development.
Leveraging Our Leadership: Increased Support for T1D Research
Through our advocacy and research leadership, JDRF influences and attracts others to support funding for cures and improving lives.
In fiscal year 2021, we drew $425.7M in additional funding and investments for T1D therapy research and development from partners in the private and public sectors. We refer to these funds as “leverage.”
This leverage is a key part of JDRF’s strategy to accelerate cures and life-improving therapies. It has empowered us to grow global support of, and investment in, T1D research, year-over-year — even during the coronavirus pandemic.
JDRF | $57.3 million
NGOs and Foundations | $17.2 million
Governments | $180.3 million
Industry Partners | $228.2 million
Download our document “Driving T1D Cures During Challenging Times” [PDF] to learn more about how JDRF globally maximized each donation in FY21 by attracting additional funding for cures research and advances to improve lives.
Your donation to JDRF is the crucial first step in the quest for a cure.